Stergios A Polyzos1, Konstantinos N Aronis2,3, Jannis Kountouras4, Dimitrios D Raptis4, Maria F Vasiloglou4, Christos S Mantzoros2,3,5. 1. Second Medical Clinic, Department of Medicine, Aristotle University of Thessaloniki, Ippokration Hospital, 49 Konstantinoupoleos, 546 42, Thessaloniki, Greece. stergios@endo.gr. 2. Division of Endocrinology, Diabetes and Metabolism, Department of Internal Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. 3. Department of Medicine, Boston Medical Center, Boston University School of Medicine, Boston, MA, USA. 4. Second Medical Clinic, Department of Medicine, Aristotle University of Thessaloniki, Ippokration Hospital, 49 Konstantinoupoleos, 546 42, Thessaloniki, Greece. 5. Section of Endocrinology, Boston VA Healthcare System, Harvard Medical School, Boston, MA, USA.
Abstract
AIMS/HYPOTHESIS: Clinical data regarding circulating leptin levels in patients with non-alcoholic fatty liver disease (NAFLD) are conflicting. The purpose of this meta-analysis was to compare leptin levels between the following groups: patients with biopsy-proven NAFLD vs controls; simple steatosis (SS) patients vs controls; non-alcoholic steatohepatitis (NASH) patients vs controls and NASH patients vs SS patients. METHODS: We performed a systematic search in PubMed, Scopus and the Cochrane Library. We analysed 33 studies, published between 1999 and 2014, including 2,612 individuals (775 controls and 1,837 NAFLD patients). RESULTS: Higher circulating leptin levels were observed in NAFLD patients vs controls (standardised mean difference [SMD] 0.640; 95% CI 0.422, 0.858), SS patients vs controls (SMD 0.358; 95% CI 0.043, 0.673), NASH patients vs controls (SMD 0.617; 95% CI 0.403, 0.832) and NASH patients vs SS patients (SMD 0.209; 95% CI 0.023, 0.395). These results remained essentially unchanged after excluding studies involving paediatric or adolescent populations and/or individuals undergoing bariatric surgery. There was moderate-to-severe heterogeneity among studies in all comparisons, but no significant publication bias was detected. Meta-regression analysis demonstrated that BMI was inversely associated with leptin SMD and accounted for 26.5% (p = 0.014) and 32.7% (p = 0.021) of the between-study variance in the comparison between NASH patients and controls and NAFLD patients and controls, respectively. However, when bariatric studies were excluded, BMI did not significantly explain the between-study variance. CONCLUSIONS/ INTERPRETATION: Circulating leptin levels were higher in patients with NAFLD than in controls. Higher levels of circulating leptin were associated with increased severity of NAFLD, and the association remained significant after the exclusion of studies involving paediatric or adolescent populations and morbidly obese individuals subjected to bariatric surgery.
AIMS/HYPOTHESIS: Clinical data regarding circulating leptin levels in patients with non-alcoholic fatty liver disease (NAFLD) are conflicting. The purpose of this meta-analysis was to compare leptin levels between the following groups: patients with biopsy-proven NAFLD vs controls; simple steatosis (SS) patients vs controls; non-alcoholic steatohepatitis (NASH) patients vs controls and NASH patients vs SS patients. METHODS: We performed a systematic search in PubMed, Scopus and the Cochrane Library. We analysed 33 studies, published between 1999 and 2014, including 2,612 individuals (775 controls and 1,837 NAFLD patients). RESULTS: Higher circulating leptin levels were observed in NAFLD patients vs controls (standardised mean difference [SMD] 0.640; 95% CI 0.422, 0.858), SS patients vs controls (SMD 0.358; 95% CI 0.043, 0.673), NASH patients vs controls (SMD 0.617; 95% CI 0.403, 0.832) and NASH patients vs SS patients (SMD 0.209; 95% CI 0.023, 0.395). These results remained essentially unchanged after excluding studies involving paediatric or adolescent populations and/or individuals undergoing bariatric surgery. There was moderate-to-severe heterogeneity among studies in all comparisons, but no significant publication bias was detected. Meta-regression analysis demonstrated that BMI was inversely associated with leptin SMD and accounted for 26.5% (p = 0.014) and 32.7% (p = 0.021) of the between-study variance in the comparison between NASH patients and controls and NAFLD patients and controls, respectively. However, when bariatric studies were excluded, BMI did not significantly explain the between-study variance. CONCLUSIONS/ INTERPRETATION: Circulating leptin levels were higher in patients with NAFLD than in controls. Higher levels of circulating leptin were associated with increased severity of NAFLD, and the association remained significant after the exclusion of studies involving paediatric or adolescent populations and morbidly obese individuals subjected to bariatric surgery.
Authors: I Pirvulescu; L Gheorghe; I Csiki; G Becheanu; M Dumbravă; S Fica; S Martin; A Sarbu; C Gheorghe; M Diculescu; C Copăescu Journal: Chirurgia (Bucur) Date: 2012 Nov-Dec
Authors: Marianna Argentou; Dina G Tiniakos; Menelaos Karanikolas; Maria Melachrinou; Maria G Makri; Christos Kittas; Fotis Kalfarentzos Journal: Obes Surg Date: 2009-07-15 Impact factor: 4.129
Authors: Jason M Hui; Alex Hodge; Geoffrey C Farrell; James G Kench; Adamandia Kriketos; Jacob George Journal: Hepatology Date: 2004-07 Impact factor: 17.425
Authors: Linda E Muñoz; Paula Cordero; Liliana Torres; Alma Y Sauceda; Juan P Flores; Jose J Segura Journal: Ann Hepatol Date: 2009 Apr-Jun Impact factor: 2.400
Authors: Rafael Bergesch D'Incao; Cristiane Valle Tovo; Vanessa Suñé Mattevi; Diego Olschowsky Borges; Jane Maria Ulbrich; Gabriela Perdomo Coral; Mauricio Jacques Ramos; Nelson Guardiola Meinhardt Journal: Obes Surg Date: 2017-08 Impact factor: 4.129
Authors: Ludovico Abenavoli; Natasa Milic; Laura Di Renzo; Tomislav Preveden; Milica Medić-Stojanoska; Antonino De Lorenzo Journal: World J Gastroenterol Date: 2016-08-21 Impact factor: 5.742